You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 12, 2024

Investigational Drug Information for simufilam


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug simufilam?

simufilam is an investigational drug.

There have been 8 clinical trials for simufilam. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2021.

The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are Cassava Sciences, Inc., National Institute on Aging (NIA), and Premier Research International LLC.

There are seven US patents protecting this investigational drug and thirty-seven international patents.

Recent Clinical Trials for simufilam
TitleSponsorPhase
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male SubjectsCassava Sciences, Inc.Phase 1
Open-label Extension for Phase 3 Clinical Trials of SimufilamCassava Sciences, Inc.Phase 3
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's DiseaseCassava Sciences, Inc.Phase 2

See all simufilam clinical trials

Clinical Trial Summary for simufilam

Top disease conditions for simufilam
Top clinical trial sponsors for simufilam

See all simufilam clinical trials

US Patents for simufilam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
simufilam ⤷  Sign Up Method of inhibiting tau phosphorylation Pain Therapeutics, Inc. (Austin, TX) ⤷  Sign Up
simufilam ⤷  Sign Up Alzheimer's disease assay in a living patient Pain Therapeutics, Inc. (Austin, TX) ⤷  Sign Up
simufilam ⤷  Sign Up Method for inhibiting growth of cancer cells Pain Therapeutics (Austin, TX) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.